Table 1.
Clinical Characteristics and Cognitive Performance of Research Participants (Mean±S.E.)
| SN Control APOEε4− (n=54) | SN Control APOEε4+ (n=16) | HIV+ APOEε4− (n=47) | HIV+ APOEε4+ (n=22) | ANOVA or Fisher’s Exact p-value | |
|---|---|---|---|---|---|
| Age (years) | 45.8 ± 1.8 | 46.0 ± 3.2 | 47.0 ± 1.2 | 48.3 ± 2.7 | 0.85 |
|
| |||||
| Younger (50 years)/Older (≥50 years) | 32 (59%)/22 (41%) | 9 (56%)/7 (44%) | 31 (66%)/16 (34%) | 11 (50%)/11 (50%) | 0.63 |
|
| |||||
| Education (years) | 14.7 ± 0.3 | 15.8 ± 0.5 | 14.7 ± 0.4 | 14.5 ± 0.5 | 0.42 |
|
| |||||
| Male Sex (%) | 49 (91%) | 13 (81%) | 44 (94%) | 19 (86%) | 0.50 |
|
| |||||
| Race: American Indian | 1 (2%) | 0 (0%) | 3 (6%) | 0 (0%) | 0.94 |
| Asian | 9 (17%) | 1 (6%) | 6 (13%) | 3 (14%) | |
| Black | 2 (4%) | 0 (0%) | 2 (4%) | 1 (5%) | |
| Native Hawaiian | 1 (2%) | 0 (0%) | 1 (2%) | 0 (0%) | |
| White | 35 (65%) | 14 (88%) | 29 (62%) | 13 (59%) | |
| Mixed | 6 (11%) | 1 (6%) | 6 (13%) | 5 (23%) | |
|
| |||||
| Ethnicity (Hispanic/Non-Hispanic) | 3 (6%)/51 (94%) | 2 (13%)/14 (87%) | 8 (17%)/39 (83%) | 2 (9%)/20 (91%) | 0.31 |
|
| |||||
| Nadir CD4 (#/mm3) | 210 ± 22.9 | 167 ± 35.9 | 0.31 | ||
|
| |||||
| CD4 (#/mm3) | 492 ± 32.6 | 348 ± 51.7 | 0.02 (Cohen’s d=−0.63) | ||
|
| |||||
| Log Viral Load (copies/mL) | 2.5 ± 0.2 | 2.8 ± 0.3 | 0.43 | ||
|
| |||||
| # (%) with Detectable Viral Load | 17 (36%) | 9 (41%) | 0.79 | ||
|
| |||||
| Karnofsky Score (0–100) | 91.8 ± 1.3 | 90.0 ± 2.1 | 0.44 | ||
|
| |||||
| HIV Dementia Scale (0–16) | 14.7 ± 0.2 | 13.8 ± 0.4 | 0.05 (Cohen’s d=−0.50) | ||
|
| |||||
| Duration HIV Diagnosis (months) | 146 ± 12.7 | 147 ± 16.1 | 0.98 | ||
|
| |||||
| # (%) on ARVs/# (%) NRTIs | 37 (79%)/36 (77%) | 18 (82%)/18 (82%) | 1.0 0.76 |
||
|
| |||||
| CES-Depression Score | 6.9 ± 0.8 | 8.8 ± 1.1 | 12.8 ± 1.4 | 11.4 ± 2.4 | 0.005a,b (η2=0.09) |
a
p<0.05 (Cohen’s d=0.77) for HIV+APOEε4− > SN Control APOEε4−
b
p<0.05 (Cohen’s d=0.53) for HIV+APOEε4+ > SN Control APOEε4−